Cwm LLC Has $1.82 Million Stake in Bruker Corporation (NASDAQ:BRKR)

CWM LLC boosted its holdings in Bruker Corporation (NASDAQ:BRKR - Free Report) by 156.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,596 shares of the medical research company's stock after purchasing an additional 26,582 shares during the quarter. CWM LLC's holdings in Bruker were worth $1,820,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in BRKR. Quadrant Capital Group LLC increased its position in Bruker by 18.2% during the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock worth $75,000 after purchasing an additional 196 shares in the last quarter. Insigneo Advisory Services LLC lifted its holdings in Bruker by 4.7% in the 4th quarter. Insigneo Advisory Services LLC now owns 4,880 shares of the medical research company's stock worth $286,000 after buying an additional 218 shares in the last quarter. CGN Advisors LLC boosted its stake in shares of Bruker by 1.4% during the 1st quarter. CGN Advisors LLC now owns 22,014 shares of the medical research company's stock valued at $919,000 after buying an additional 296 shares during the last quarter. New York State Teachers Retirement System raised its position in shares of Bruker by 0.8% during the 1st quarter. New York State Teachers Retirement System now owns 37,115 shares of the medical research company's stock valued at $1,549,000 after acquiring an additional 300 shares in the last quarter. Finally, State of Michigan Retirement System boosted its position in Bruker by 1.1% during the 1st quarter. State of Michigan Retirement System now owns 26,493 shares of the medical research company's stock valued at $1,106,000 after purchasing an additional 300 shares during the period. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Trading Up 6.5%

NASDAQ:BRKR traded up $2.32 during midday trading on Tuesday, hitting $37.95. 1,986,519 shares of the company traded hands, compared to its average volume of 1,829,110. The firm has a market capitalization of $5.75 billion, a P/E ratio of 73.09, a P/E/G ratio of 2.73 and a beta of 1.18. The company has a current ratio of 1.57, a quick ratio of 0.74 and a debt-to-equity ratio of 1.13. Bruker Corporation has a 12-month low of $34.10 and a 12-month high of $72.94. The firm's fifty day moving average is $39.43 and its 200-day moving average is $44.79.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical research company reported $0.47 EPS for the quarter, beating analysts' consensus estimates of $0.46 by $0.01. Bruker had a net margin of 2.31% and a return on equity of 19.47%. The business had revenue of $801.40 million during the quarter, compared to analysts' expectations of $763.83 million. During the same period in the prior year, the business earned $0.53 earnings per share. The company's quarterly revenue was up 11.0% compared to the same quarter last year. On average, sell-side analysts predict that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Monday, June 16th were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date of this dividend was Monday, June 16th. Bruker's dividend payout ratio is presently 38.46%.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. The Goldman Sachs Group dropped their target price on Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Bank of America dropped their price target on shares of Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Wells Fargo & Company lowered their price objective on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a research report on Thursday, April 17th. Stifel Nicolaus dropped their target price on shares of Bruker from $57.00 to $48.00 and set a "hold" rating on the stock in a report on Thursday, May 8th. Finally, Citigroup lowered Bruker from a "strong-buy" rating to a "hold" rating and lowered their price objective for the stock from $50.00 to $40.00 in a research note on Thursday, May 22nd. Six research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $52.89.

Insiders Place Their Bets

In other Bruker news, CEO Frank H. Laukien purchased 2,608 shares of the stock in a transaction on Friday, June 6th. The stock was bought at an average price of $38.36 per share, for a total transaction of $100,042.88. Following the acquisition, the chief executive officer directly owned 38,462,171 shares of the company's stock, valued at $1,475,408,879.56. This represents a 0.01% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Insiders own 27.30% of the company's stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.